A new diet pill Contrave got approval to be sold in the United States on ... or hospitalizations, then ... the market would be reignited,” said Lang,
Basher on duty ...How much do you get paid?
Under the terms of the agreement, Orexigen will receive an upfront cash payment of $50 million from Takeda, and Takeda will obtain an exclusive marketing right from Orexigen in the United States, Mexico and Canada while Orexigen retains the right to co-promote with Takeda in the United States. Orexigen will be eligible to receive payments of over $1 billion upon achieving certain regulatory and sales-based milestones. Assuming Contrave is commercialized, Takeda will pay tiered double-digit royalty payments on net sales in the Territory.
It's Not Too Late to Buy Apple -- but Hurry Up
Wells Fargo analyst thinks Contrave could one day pull in sales of more than $600 million a year.
If that estimate proves correct, it would seem Orexigen's shares may be pretty cheap. After all, its market cap is just $646 million.
The Apple Store has been unavailable for certain periods of time since the launch (for us, at least two hours), and those who have been able to access it have had problems actually going through with their order. Some also found that the 64GB and the 128GB iPhone 6 Plus models are unavailable
Vivus Inc’s Qsymia and Arena Pharmaceuticals Inc’s Belviq, both are weak.
900 Sales force welcomed by the Dr. with this
In my clinic, I often treat patients who fit these criteria, and now, with the approval of Contrave, I am excited to have a new treatment option to consider for my patients."
At Cumberland Advisors, we do not own single stocks. Only exchange-traded funds are used as our stock market portfolio management tools. Our ETF strategy silos take several different forms. Apple is such a large weight that it gets into many of those funds automatically. Since we are overweight the Tech sector, that strategy puts us in the position of holding Apple and watching it rise.
Our conclusion is that Apple could become a true trillion-dollar company if it continues to innovate and expand, to add services to its hardware, and to do so in an orderly and thoughtful way. The opportunity presents itself in this modern and highly technological world. And we like the Tech sector with our ETF strategies. Apple is a large company, but it is only one component of the Tech sector.
Wells Fargo analyst Matthew Andrews expects Contrave’s US sales to eclipse that of Belviq and Qsymia by 2016.
Contrave sales are expected to be about $200m in 2016, slightly higher than Belviq’s $180m and well ahead of Qsymia’s $150m, said Andrews, who covers all three companies.
“If these obesity cardiovascular outcomes trials do show that they reduce heart attacks, or hospitalizations, then ... the market would be reignited,” said Lang, a trained cardiologist.
Orexigen’s Contrave, slated to enter Europe before both Qsymia and Belviq, is licensed in North America to Takeda Pharmaceutical Co.
It will be marketed by a 900-strong sales force, compared with Arena and partner Eisai Co’s 600 and Vivus’ even smaller sales force.